Risk of Severe Outcomes From COVID-19 in Comorbid Populations in the Omicron Era: A Meta-analysis
Chapman, A.; Barouch, D. H.; Lip, G. Y. H.; Pliakas, T.; Polverino, E.; Sourij, H.; Abduljawad, S.
Show abstract
ImportanceThis is the first meta-analysis to investigate risk of death and hospitalization in individuals with comorbidities, specifically during the Omicron era. ObjectiveTo assess the risk of mortality and hospitalization from COVID-19 in individuals with comorbidities in comparison with individuals without comorbidities during the Omicron era. Data SourcesA systematic search of Embase, MEDLINE, PubMed, Europe PMC, Latin American and Caribbean Health Sciences Literature, Cochrane COVID-19 Study Register, and WHO COVID-19 Database was performed to identify studies published between 1 January 2022 and 13 March 2024. Study SelectionInclusion criteria were observational studies including people (all ages) with at least 1 of the following comorbidities: cardiovascular/ cerebrovascular disease, chronic lung conditions, diabetes, and obesity. In total, 72 studies were included in the review, of which 68 were meta-analyzed. Data Extraction and SynthesisData were extracted by one reviewer and verified by a second. Studies were synthesized quantitively (meta-analysis) using random-effect models. PRISMA guidelines were followed. Main Outcomes and MeasuresEvaluated outcomes were the risks of death, hospitalization, intensive care unit (ICU) admission, and any combination of these outcomes. Odds ratios, hazard ratios, and rate ratios were extracted; pooled relative risk (RR) and 95% confidence intervals (CI) were calculated. ResultsMinimum numbers of participants per comorbidity across included studies ranged from 328 870 for thrombosis to 13 720 480 for hypertension. Risks of death, hospitalization, and the combined outcome were increased in individuals with cerebrovascular disease, COPD, diabetes, respiratory diseases, heart disease, and heart failure versus those without (pooled RRs ranged from 1.27 [heart disease, hospitalization; 95% CI, 1.17-1.38, P < .001] to 1.78 [heart failure, death: 95% CI, 1.46-2.16, P < .001]). Individuals with diabetes and obesity had increased risk of ICU admission (RR: 1.20; 95% CI: 1.04-1.38, P = .0141 and RR: 1.32; 95% CI: 1.11-1.57, P = .00158, respectively). ConclusionsDuring the Omicron era, risk of death and hospitalization from COVID-19 is increased amongst individuals with comorbidities including cerebrovascular/cardiovascular conditions, chronic lung diseases, and diabetes, with the highest risk in those with heart failure. Individuals with diabetes and obesity are at increased risk of ICU admission. Key PointsO_ST_ABSQuestionC_ST_ABSWhat are the risks of severe outcomes from COVID-19 in individuals with comorbidities during the Omicron era? FindingsThis systematic review and meta-analysis found increased risk of mortality and hospitalization among individuals with a range of comorbidities, including cerebrovascular/cardiovascular conditions, chronic lung diseases, and diabetes, with the highest risk in those with heart failure, versus those without. Risk of ICU admission was higher in individuals with obesity and diabetes. MeaningThis study identified comorbid populations most at risk of severe outcomes from COVID-19. Targeting these populations with public health measures, such as vaccination, may be beneficial.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The protective association between statins use and adverse outcomes among COVID-19 patients: a systematic review and meta-analysis 95%
- Can we predict the severe course of COVID-19 – a systematic review and meta-analysis of indicators of clinical outcome? 94%
- Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis 94%
Similar papers in this journal
- Cardiovascular risk factors are independently associated with COVID-19 mortality: a prospective cohort study 94%
- Risk factors for severity on admission and the disease progression during hospitalization in a large cohort of COVID-19 patients in Japan 93%
- Combined association of obesity and other cardiometabolic diseases with severe COVID-19 outcomes: a nationwide cross-sectional study of 21,773 Brazilian adult and elderly inpatients 93%
Similar papers in this journal
- Global Prevalence of Post-Acute Sequelae of COVID-19 (PASC) or Long COVID: A Meta-Analysis and Systematic Review 94%
- Low grade systemic inflammation is a risk factor for infection death: an observational cohort study 92%
- Statins Are Associated with Improved 28-day Mortality in Patients Hospitalized with SARS-CoV-2 Infection 91%
Similar papers in this journal
- Which children and young people are at higher risk of severe disease and death after SARS-CoV-2 infection: a systematic review and individual patient meta-analysis 95%
- Effectiveness of Rosuvastatin plus Colchicine, Emtricitabine/Tenofovir and a combination of them in Hospitalized Patients with SARS Covid-19 93%
- The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial 91%
Similar papers in this journal
- Cardiopulmonary exercise testing to evaluate post-acute sequelae of COVID-19 (“Long COVID”): a systematic review and meta-analysis 92%
- COVID-19 outcomes, risk factors and associations by race: a comprehensive analysis using electronic health records data in Michigan Medicine 91%
- Corticosteroids in COVID-19: Optimizing Observational Research through Target Trial Emulations 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.